Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Count Me In! China To Update Drug Coverage After Long Wait

Executive Summary

After a long seven-year hiatus, China is finally moving to update its national reimbursement drug list, but the process will involve huge numbers of experts and the benefits of inclusion may not be as immediate or as extensive as appear at first sight.

Advertisement

Related Content

Pfizer Still Bullish On China
China Leads Strong AstraZeneca Emerging Markets Charge In Q1
2016 Review: Rapid Change Defines China Regulatory Environment
The ‘Sanming Model’: Bad Omen Or Hope For Pharma In China?
Where Is The Reward? New Drug Developers See Red In China
Deep China Price Cuts Reveal Complex Considerations

Topics

Related Companies

Related Deals

What to read next

Advertisement
UsernamePublicRestriction

Register

PS119295

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel